Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.704 +0.514 (+43.23%)
Streaming Delayed Price Updated: 3:39 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 44,996,771
Open 1.360
Bid (Size) 1.700 (62)
Ask (Size) 1.710 (36)
Prev. Close 1.190
Today's Range 1.200 - 1.960
52wk Range 1.130 - 2.550
Shares Outstanding 49,046,246
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks have an unusual volume in today's session
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga

Performance

YTD
-20.0%
-20.0%
1 Month
+34.2%
+34.2%
3 Month
+28.6%
+28.6%
6 Month
+15.9%
+15.9%
1 Year
-2.6%
-2.6%

More News

Read More
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?
Via Benzinga
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
Via Stocktwits
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
From MediciNova, Inc.
Via GlobeNewswire
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Provides Shareholder Update on Key Developments
From MediciNova, Inc.
Via GlobeNewswire
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
From MediciNova, Inc.
Via GlobeNewswire
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
From MediciNova, Inc.
Via GlobeNewswire
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
From MediciNova, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MediciNova, Inc. - Common Stock publicly traded?
Yes, MediciNova, Inc. - Common Stock is publicly traded.
What exchange does MediciNova, Inc. - Common Stock trade on?
MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MediciNova, Inc. - Common Stock?
The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
What is the current price of MediciNova, Inc. - Common Stock?
The current price of MediciNova, Inc. - Common Stock is 1.704
When was MediciNova, Inc. - Common Stock last traded?
The last trade of MediciNova, Inc. - Common Stock was at 10/31/25 03:39 PM ET
What is the market capitalization of MediciNova, Inc. - Common Stock?
The market capitalization of MediciNova, Inc. - Common Stock is 83.59M
How many shares of MediciNova, Inc. - Common Stock are outstanding?
MediciNova, Inc. - Common Stock has 84M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.